10-K Decoder · All companies

Lineage Cell Therapeutics, Inc.

LCTX · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Mar 2026

Open the dashboardInfographicSummary

FY2025 key figures

$FY2025FY2024Change
Revenue$14.6M$9.50M+53.3%
Operating income−$36.6M−$21.5M−70.5%
Net income−$63.5M−$18.6M−241%

Latest quarter: Q3 2026

Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 12, 2026

$Q3 2026Year earlierChange
Revenue$1.40M$3.70M−62.2%
Operating income−$7.30M−$3.80M−92.1%
Net income$4.20M−$29.8M

Q3 2026 dashboardQ3 2026 infographic

Questions

What was Lineage Cell's revenue in FY2025?
$14.6M in FY2025 (Fiscal year ended Dec 31, 2025), +53.3% vs $9.50M a year earlier, per its 10-K filed Mar 2026.
Was Lineage Cell profitable in FY2025?
No: net income was −$63.5M and operating income −$36.6M in FY2025.
What was Lineage Cell's revenue in Q3 2026?
$1.40M (−62.2% vs a year earlier), per its Form 10-Q filed Nov 12, 2026.